Respiratorius AB (publ) (NGM:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
6.10
+0.02 (0.33%)
At close: Apr 9, 2025
-74.48%
Market Cap 31.71M
Revenue (ttm) n/a
Net Income (ttm) -7.57M
Shares Out 5.10M
EPS (ttm) -1.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 726
Average Volume 4,539
Open 5.80
Previous Close 6.08
Day's Range 5.80 - 6.10
52-Week Range 3.56 - 10.00
Beta 1.84
RSI 53.57
Earnings Date May 20, 2025

About Respiratorius AB

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Other
Founded 1998
Employees 1
Stock Exchange Nordic Growth Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.